Aveo Pharmaceuticals Inc (NASDAQ:AVEO)
| 2.70 Data as of May 23 |  +0.04 / +1.50%Today’s Change | 2.25 Today|||52-Week Range 14.08 | -66.46% Year-to-Date |
Latest AVEO News | Press Releases
| 2013 FDA Drug Approval Calendar May 21 / TheStreet.com |
Today’s Trading
| Previous close | 2.66 |
| Today’s open | 2.68 |
| Day’s range | 2.55 - 2.74 |
| Volume | 2,487,368 |
| Average volume (3 months) | 1,984,539 |
| Market cap | $138.0M |
| Dividend yield | -- |
Data as of 4:00pm ET, 05/23/2013
Growth & Valuation
| Earnings growth (last year) | -456.76% |
| Earnings growth (this year) | +11.62% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -88.30% |
| P/E ratio | NM |
| Price/Sales | 18.10 |
| Price/Book | 0.98 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| KBIOKaloBios Pharmaceuti... | -0.04 | -0.70% |
| ALIMAlimera Sciences Inc | +0.01 | +0.23% |
| APPAA.P. Pharma Inc | -0.02 | -3.41% |
| PTXPernix Therapeutics ... | +0.03 | +0.84% |
Data as of 4:00pm ET, 05/23/2013
Financials
| Next reporting date | August 1, 2013 |
| EPS forecast (this quarter) | -$0.57 |
| Annual revenue (last year) | $19.3M |
| Annual profit (last year) | -$114.4M |
| Net profit margin | -593.15% |
Profile
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Tuan Ha-Ngoc, MBA |
Chief Operating Officer & Executive Vice President Elan Z. Ezickson |
Corporate headquarters Cambridge, Massachusetts |
Forecasts
